Ixekizumab

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Generalized Pustular Psoriasis

Conditions

Generalized Pustular Psoriasis, Erythrodermic Psoriasis

Trial Timeline

Jul 5, 2019 → Jul 22, 2020

NCT ID

NCT03942042

About Ixekizumab

Ixekizumab is a approved stage product being developed by Eli Lilly for Generalized Pustular Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03942042. Target conditions include Generalized Pustular Psoriasis, Erythrodermic Psoriasis.

What happened to similar drugs?

11 of 20 similar drugs in Generalized Pustular Psoriasis were approved

Approved (11) Terminated (3) Active (8)

✅Duloxetine + PlaceboEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Alprazolam (Xanax) + PlaceboRocheApproved

✅Ziprasidone + PlaceboPfizerApproved

✅Pregabalin + Lorazepam + Pregabalin + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05855967	Approved	Completed	Jun 27, 2023	Sep 23, 2024	Plaque Psoriasis
NCT04259346	Phase 1	Completed	Feb 5, 2020	Feb 19, 2021	Healthy
NCT03942042	Approved	Completed	Jul 5, 2019	Jul 22, 2020	Generalized Pustular Psoriasis
NCT03848416	Phase 1	Completed	Jan 29, 2019	Jun 7, 2019	Healthy
NCT03848403	Phase 1	Terminated	Jan 29, 2019	Jul 18, 2019	Healthy
NCT03485976	Phase 2	Completed	May 23, 2018	Jan 13, 2020	Pityriasis Rubra Pilaris
NCT03099538	Phase 2	Completed	Aug 15, 2017	Jun 6, 2019	Bullous Pemphigoid
NCT03137160	Phase 2	Completed	May 4, 2017	Aug 16, 2018	Pyoderma Gangrenosum
NCT03073213	Phase 1	Completed	Apr 13, 2017	May 14, 2019	Psoriasis
NCT02387801	Phase 3	Completed	Apr 1, 2015	Aug 1, 2016	Psoriasis

Competing Products

20 competing products in Generalized Pustular Psoriasis

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40
Quetiapine fumarate + Paroxetine	AstraZeneca	Phase 3	40